A first-in-human clinical study of PRP for the treatment of cancer

Trial Profile

A first-in-human clinical study of PRP for the treatment of cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Chymotrypsinogen/trypsinogen (Primary)
  • Indications Colorectal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 04 Jan 2017 According to a Propanc media release, company plans to submit an investigational medicine product dossier (IMPD) and clinical trial application (CTA) for PRP in the UK in 2017.
    • 15 Sep 2016 New trial record
    • 07 Sep 2016 According to a Propanc Health Group media release, the company submitted an application for orphan medicinal product designation (OMPD) to the EMA for PRP for the treatment of pancreatic cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top